OLSSON, AG, P PAUCIULLO, Vladimír SOŠKA, P LULEY, RE PIETERS, G BRODA and B PALACIOS. Comparison of the efficacy and tolerability of fluvastatin extended-release and immediate-release formulations in the treatment of primary hypercholesterolemia: a randomized trial. Clin Ther. UNITED STATES: ELSEVIER, 2001, vol. 23, No 1, p. 45-61. ISSN 0149-2918.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Comparison of the efficacy and tolerability of fluvastatin extended-release and immediate-release formulations in the treatment of primary hypercholesterolemia: a randomized trial.
Name (in English) Comparison of the efficacy and tolerability of fluvastatin extended-release and immediate-release formulations in the treatment of primary hypercholesterolemia: a randomized trial.
Authors OLSSON, AG, P PAUCIULLO, Vladimír SOŠKA, P LULEY, RE PIETERS, G BRODA and B PALACIOS.
Edition Clin Ther, UNITED STATES, ELSEVIER, 2001, 0149-2918.
Other information
Type of outcome Article in a journal
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 2.721
Organization unit Faculty of Medicine
Keywords in English Fluvastatin; hypercholesterolemia
Changed by Changed by: prof. MUDr. Vladimír Soška, CSc., učo 34422. Changed: 16/3/2011 13:38.
Abstract
The purpose of this study was to compare the lipid-lowering efficacy and tolerability of fluvastatin ER (80 mg once daily) versus fluvastatin immediate-release (IR) (40 mg once or twice daily). Of the 1183 patients enrolled, 695 were randomly assigned to treatment 346 to fluvastatin ER 80 mg QPM, 174 to fluvastatin IR 40 mg QPM, and 175 to fluvastatin IR 40 mg BID. Patients were well matched between groups, with a mean age of 56 years and body mass index of 27 kg/m2; 56.0% of patients (389/695) were female and 97.7% (679/695) were white. Fluvastatin ER 80 mg QPM lowered LDL-C levels significantly
Abstract (in English)
The purpose of this study was to compare the lipid-lowering efficacy and tolerability of fluvastatin ER (80 mg once daily) versus fluvastatin immediate-release (IR) (40 mg once or twice daily). Of the 1183 patients enrolled, 695 were randomly assigned to treatment 346 to fluvastatin ER 80 mg QPM, 174 to fluvastatin IR 40 mg QPM, and 175 to fluvastatin IR 40 mg BID. Patients were well matched between groups, with a mean age of 56 years and body mass index of 27 kg/m2; 56.0% of patients (389/695) were female and 97.7% (679/695) were white. Fluvastatin ER 80 mg QPM lowered LDL-C levels significantly
PrintDisplayed: 26/9/2024 12:54